2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease
Authors, Journal, Affiliations, Type, DOI
- Authors: Eric M. Isselbacher (Chair), Ourania Preventza and James Hamilton Black III (Vice Chairs), with a writing committee spanning cardiology, cardiac surgery, vascular surgery, radiology, anaesthesiology, genetics and patient representation
- Journal: Circulation. 2022;146:e334–e482
- Collaborating organisations: Developed in collaboration with and endorsed by the American Association for Thoracic Surgery, American College of Radiology, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons and Society for Vascular Surgery; endorsed by the Society of Interventional Radiology and Society for Vascular Medicine
- Type: ACC/AHA clinical practice guideline — the first US guideline to cover the entire aorta rather than thoracic or abdominal segments separately
- DOI: https://doi.org/10.1161/CIR.0000000000001106
Overview
This is the guideline that moved aortic disease from diameter-triggered surgery toward a body-size-indexed, team-based, patient-specific decision. Its most consequential change is the lowering of the sporadic aortic root and ascending repair threshold from 5.5 cm to 5.0 cm in selected patients at centres with Multidisciplinary Aortic Teams, and lower still for heritable thoracic aortic disease. It also redefines the vocabulary: a thoracic aorta is "dilated" at 4.0 cm and an "aneurysm" at 4.5 cm — not the conventional 1.5 × normal — on the basis of an abrupt step up in dissection risk at that size.
Four structural decisions shape the document. First, it treats acute aortic dissection, intramural haematoma, penetrating atherosclerotic ulcer and blunt traumatic aortic injury as one family with shared diagnostic logic. Second, it makes the Multidisciplinary Aortic Team a prerequisite embedded in recommendation wording rather than an aspiration. Third, it quantifies growth as an intervention trigger on its own — ≥0.5 cm in one year, or ≥0.3 cm/year over two consecutive years, and ≥0.3 cm in one year for HTAD or bicuspid aortic valve. Fourth, it recommends first-degree relative screening for anyone with an aortic root/ascending aneurysm or a dissection.
Keywords
Aortic disease · aortic aneurysm · thoracic aortic aneurysm · abdominal aortic aneurysm · thoracoabdominal aortic aneurysm · acute aortic syndrome · aortic dissection · intramural haematoma · penetrating atherosclerotic ulcer · bicuspid aortic valve · heritable thoracic aortic disease · Marfan syndrome · Loeys-Dietz syndrome · vascular Ehlers-Danlos syndrome · Turner syndrome · shared decision-making · Multidisciplinary Aortic Team · TEVAR · EVAR · valve-sparing root replacement · pregnancy
Key Takeaways
Definitions and measurement
- Dilated thoracic aorta = ≥4.0 cm; aneurysm = ≥4.5 cm. The conventional "1.5 × expected diameter" definition is explicitly rejected for the root and ascending aorta, because it would place the threshold above the size at which repair is already recommended.
- The justification is risk-based: relative to ≤3.4 cm, a diameter of 4.0–4.4 cm carries an 89-fold increased risk of type A dissection, and ≥4.5 cm a 6000-fold increase (relative, not absolute, risk).
- Diameters must be measured perpendicular to the axis of blood flow, at reproducible landmarks, inner-edge to inner-edge on ECG-gated CT/MR, and leading-edge to leading-edge on echocardiography. The root is reported as the maximum sinus-to-sinus measurement, with both long- and short-axis images when asymmetric.
- Index to body size when the patient is unusually short or tall: aortic size index (diameter/BSA), aortic height index (diameter/height), or cross-sectional area/height ≥10 cm²/m.
Imaging
- TTE at diagnosis to assess valve anatomy, valve function and thoracic diameters; CT or MRI at diagnosis to assess the whole thoracic aorta.
- CT with ECG synchronisation is the emergency gold standard for suspected acute aortic syndrome; TEE and MRI are reasonable alternatives.
Growth and natural history
- Mean growth rates: Marfan aortic root 0.26 cm/year (0.46 cm/year above 6.0 cm); BAV root phenotype 0.06 cm/year and ascending phenotype 0.03 cm/year; tricuspid sporadic ascending aorta as little as 0.01 cm/year; arch 0.25 cm/year; descending/thoracoabdominal 0.19 cm/year; AAA 0.26 cm/year (up to 0.5 cm/year when large).
Surveillance intervals
- Thoracic dilation: TTE at diagnosis; CT/MRI at diagnosis; follow-up at 6–12 months to establish the growth rate, then every 6–24 months depending on diameter.
- AAA: 3.0–3.9 cm every 3 years; men 4.0–4.9 cm and women 4.0–4.4 cm annually; men ≥5.0 cm and women ≥4.5 cm every 6 months. Ultrasound is the modality; CT when ultrasound is inadequate.
Repair thresholds
| Segment / context | Threshold | COR |
|---|---|---|
| Symptomatic aortic root/ascending | Any size | 1 |
| Sporadic root/ascending, asymptomatic | ≥5.5 cm | 1 |
| Sporadic root/ascending, experienced team | ≥5.0 cm | 2a |
| Growth | ≥0.5 cm in 1 year or ≥0.3 cm/year × 2 years | 1 |
| Area/height ratio | ≥10 cm²/m | 2a |
| Aortic arch, asymptomatic, low risk | ≥5.5 cm | 2a |
| Descending TAA | ≥5.5 cm | 1 |
| Thoracoabdominal, degenerative | ≥6.0 cm (≥5.5 cm in expert hands) | 1 / 2a |
| AAA, men / women | ≥5.5 cm / ≥5.0 cm | 1 (Level A) |
| BAV | ≥5.5 cm; 5.0–5.4 cm with a risk factor (2a); ≥4.5 cm at concomitant AVR (2a) | — |
| Marfan | ≥5.0 cm; ≥4.5 cm with risk features (2a) | 1 |
| Loeys-Dietz | Gene-specific — e.g. ACTA2 ~4.5 cm, PRKG1 ~4.2 cm | 2a/2b |
| Turner | ASI ≥2.5 cm/m² plus risk factors | 2a |
- Coexisting aortic valve disease lowers the threshold: ascending replacement at ≥4.5 cm during tricuspid valve surgery in an experienced team (2a), and ≥4.5 cm during BAV valve surgery (2a).
Medical therapy
- Sporadic TAA: beta-blocker to target BP (2a); ARB as adjunct (2a); statin where atherosclerosis is present (2a); low-dose aspirin where atheroma or PAU is present (2a).
- AAA: antihypertensive therapy when average SBP ≥130 or DBP ≥80 mmHg (1); statin where atherosclerosis is present (1); smoking cessation (1).
- Acute aortic syndrome: anti-impulse therapy under arterial-line monitoring in an ICU, with SBP <120 mmHg or the lowest pressure maintaining end-organ perfusion, and heart rate 60–80/min (1). IV beta-blocker first (1); non-dihydropyridine calcium channel blocker if beta-blockade is contraindicated (2a); IV vasodilator only after beta-blockade (1); analgesia as a haemodynamic measure (1).
- Long term: beta-blocker for life where tolerated (1), with ACE-I/ARB added as needed.
Acute aortic syndrome
- Diagnosis: CT first-line (1); TEE or MRI reasonable alternatives (2a). No biomarker is diagnostic, but a low probability plus D-dimer <500 ng/mL makes the diagnosis unlikely.
- Type A dissection: emergency surgery (1), transfer to a high-volume centre if the patient is stable (2a), and surgery even with non-haemorrhagic stroke complicating the dissection (2a). Aortic valve resuspension over replacement when the leaflets are intact (1); open distal anastomosis (1); hemiarch over total arch when there is no arch tear or aneurysm (1).
- Malperfusion: immediate proximal repair for renal, mesenteric or limb malperfusion (1); for mesenteric malperfusion, either immediate ascending repair or immediate mesenteric revascularisation first is reasonable (2a).
- Type B dissection: medical therapy for all uncomplicated cases (1); intervention for rupture or complications (1), endovascular preferred where anatomy allows. TEVAR may be considered in uncomplicated type B with high-risk anatomy (2b, Level B-R).
- Intramural haematoma: uncomplicated type A → prompt open repair (1), with medical management an option in selected high-risk patients without high-risk imaging features (2b); uncomplicated type B → medical therapy (1); complicated type B → TEVAR.
- Penetrating ulcer: PAU with rupture or ascending PAU with IMH → urgent repair (1); arch/descending PAU with IMH → urgent repair is reasonable (2a); symptomatic isolated PAU with persistent pain → repair (1); asymptomatic isolated PAU with high-risk features → elective repair may be considered (2b). Open repair for zones 0–1; either modality for zones 2+.
- Long-term surveillance after AAS is lifelong — the disease involves the entire aorta.
Pregnancy
- Imaging before pregnancy; beta-blocker throughout pregnancy and postpartum; TTE each trimester and several weeks postpartum; MRI without gadolinium rather than CT for the arch/descending/abdominal aorta.
- Surgery before pregnancy: Marfan root >4.5 cm (1), 4.0–4.5 cm may be considered (2b); nsHTAD ≥4.5 cm (1); BAV ≥5.0 cm (1); sporadic ≥5.0 cm (1); Turner ASI ≥2.5 cm/m² (1).
- Delivery: vaginal delivery if aortic diameter <4.0 cm (1); caesarean reasonable at ≥4.5 cm (2a); caesarean recommended after chronic dissection (1).
- Acute type A dissection in the third trimester: caesarean immediately followed by aortic surgery (1); first or second trimester: aortic surgery with fetal monitoring (1).
Team, relatives and activity
- Multidisciplinary Aortic Teams, shared decision-making, and referral of complex cases to centres performing at least 30–40 aortic procedures annually.
- First-degree relative screening with aortic imaging is recommended for patients with aortic root/ascending aneurysm or dissection (1).
- Avoid intense isometric exercise, burst exertion and collision sports in significant aortic disease (1); 30–60 minutes of mild-to-moderate aerobic activity 3–4 days per week is reasonable when BP is controlled (2a).
Limitations of the document
- Nearly all recommendations are Level C. Of the 260 recommendations extracted, the great majority rest on expert opinion or limited data, including many of the size thresholds that carry Class 1. Level A appears only for AAA repair thresholds, TAAA spinal cord and renal protection, and three medical therapy items.
- The 5.0 cm threshold is conditional on the operator and the institution, not on the patient. It applies "when performed by experienced surgeons in a Multidisciplinary Aortic Team" — an unmeasurable qualifier that makes the recommendation untestable outside those centres.
- The definition of "aneurysm" at 4.5 cm is a US consensus choice and differs from the ESC 2024 approach, which prefers the term significant aortic dilatation with the diameter specified and treats 40 mm (men) / 36 mm (women) as the practical threshold for suspecting dilatation.
- Pregnancy recommendations are extrapolated from small series; the harms of aortic surgery in pregnancy are not quantified.
- No cost-effectiveness modelling, and only limited attention to sex- and ancestry-specific thresholds despite acknowledging that women dissect at smaller diameters.
- The guideline is US-centric on device availability and regulatory approval (FDA-approved fenestrated devices).
Key Concepts Mentioned
concepts/Acute-Aortic-Syndrome · concepts/Thoracic-Aortic-Aneurysm · concepts/Abdominal-Aortic-Aneurysm · concepts/Acute-Aortic-Syndrome · concepts/Heritable-Thoracic-Aortic-Disease · entities/Marfan-Syndrome · entities/Bicuspid-Aortic-Valve · concepts/Aortic-Regurgitation · concepts/Aortic-Stenosis
Key Entities Mentioned
Marfan syndrome · Loeys-Dietz syndrome · vascular Ehlers-Danlos syndrome · Turner syndrome · Takayasu arteritis · giant cell arteritis
Wiki Pages Updated
- concepts/Acute-Aortic-Syndrome — created
- concepts/Thoracic-Aortic-Aneurysm — created
- concepts/Abdominal-Aortic-Aneurysm — created
- concepts/Heritable-Thoracic-Aortic-Disease — created
- concepts/Acute-Aortic-Syndrome — updated
- entities/Bicuspid-Aortic-Valve — updated
- entities/Marfan-Syndrome — updated
- concepts/Aortic-Regurgitation — updated
- index — hub entries added